Eli Lilly says EloraTZP cut weight up to 23.3% vs 14.8% for tirzepatide in Phase 2b diabetes trial; Phase 3 planned for Q4

Eli Lilly said its experimental obesity drug EloraTZP produced weight loss of up to 23.3% in a Phase 2b diabetes trial, versus 14.8% for tirzepatide. The company plans to start Phase 3 testing in the fourth quarter.

Detected & updated continuously · Source: Nebula